Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer
Authors:
Open Access
- 16 February 2010
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 102 (5) , 827-832
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancerBreast Cancer Research, 2009
- Highly frequent anti‐idiotype antibody in cynomolgus monkeys developed against mouse‐derived regions of anti‐Fas antibody humanized by complementarity determining region graftingBritish Journal of Pharmacology, 2009
- Population Pharmacokinetics and Dosing Recommendations for Cisplatin during Intraperitoneal Peroperative AdministrationClinical Pharmacokinetics, 2009
- The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?British Journal of Clinical Pharmacology, 2008
- Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer developmentBritish Journal of Cancer, 2008
- Population pharmacokinetics–pharmacodynamics of alemtuzumab (Campath®) in patients with chronic lymphocytic leukaemia and its link to treatment responseBritish Journal of Clinical Pharmacology, 2007
- Exposure-Effect Population Model of Inolimomab, a Monoclonal Antibody Administered in First-Line Treatment for Acute Graft-Versus-Host DiseaseClinical Pharmacokinetics, 2007
- Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of GliclazidePharmaceutical Research, 2006
- Time and Theophylline Concentration Help Explain the Recovery of Peak Flow Following Acute Airways ObstructionClinical Pharmacokinetics, 1993
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976